Investigation of paclitaxel-carboplatin one-cycle neoadjuvant chemotherapy plus trastuzumab in HER2-positive breast cancer

摘要

Objective: This study aims to observe the curative effects and safety of paclitaxel-carboplatin one-cycle neoadjuvant chemotherapy plus trastuzumab on HER2-positive breast cancer. Materials and Methods: Forty-two patients with HER2-positive breast cancer were included into this study. These patients underwent paclitaxel-carboplatin one-cycle neoadjuvant chemotherapy plus trastuzumab therapy for four courses of treatment. Paclitaxel (80 mg/m(2)) and carboplatin (AUC 1.5) were administered via i.v. g.t.t., dl, repeated every week. Three weeks was considered as one course of treatment, and there were 12 weeks in total. At the same time, trastuzumab (Herceptin) one-cycle therapy was combined. Its efficacy and adverse reactions were evaluated, and the major observational indicator was pathological complete remission (pCR). Results: A total of 41 patients successfully underwent paclitaxel-carboplatin one-cycle neoadjuvant chemotherapy plus trastuzumab therapy for four courses of treatment. and the total clinical effective rate was 97.6%. Clinical complete remission (CR) was achieved by 25 patients (59.5%), partial remission (PR) of the tumor was achieved by 16 patients (38.1%), and pCR was achieved by 23 patients (54.8%). Adverse reactions included bone marrow suppression and hair loss, and no toxic and adverse reactions of the heart were observed. Conclusion: In the neoadjuvant chemotherapy of HER-2-positive breast cancer, paclitaxel-carboplatin one-cycle neoadjuvant chemotherapy plus trastuzumab therapy for four courses of treatment achieved better efficacy and tolerance.